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Founded in 1947, the European League
Against Rheumatism (EULAR) is a European
umbrella organisation that represents 45
national scientific rheumatological societies,
37 organisations of people with arthritis/
rheumatism and 18 health professionals asso-
ciations throughout Europe.
In 2015, EULAR will have a total of 100
members.
The aims of EULAR are to reduce the
burden of rheumatic and muskuloskeletal
diseases (RMD) on individual and society
levels and to improve its treatment, preven-
tion and aid in rehabilitation. To this end,
EULAR fosters excellence in education and
research in the field of rheumatology. It pro-
motes the translation of research advances
into daily care and fights for recognition of
the needs of people with rheumatic diseases.
At the European political level, EULAR
represents the interests of the entire rheum-
atic disease community and is a natural
partner of European policy makers by whom
policies and regulatory frameworks are devel-
oped. Since 2013, RMDs have been recog-
nised by the EU Commission as being among
the major five chronic diseases, and substan-
tial investments into research are being
planned.
EULAR is a truly pan-European organisa-
tion fostering a multitude of activities includ-
ing education and training in rheumatology.
Every year, EULAR sponsors a number of edu-
cational grants and bursaries for scientific
researchers, clinicians and health profes-
sionals, and people with arthritis/rheumatism,
tailored to support experts in developing their
skills and expertise, and broadening their
network of contacts at the European and
international level.
Furthermore, EULAR offers an extensive
programme of traditional and online educa-
tional workshops and courses for trainee and
specialised rheumatologists. These include
the EULAR Postgraduate Course, which seeks
to harmonise and update the professional
knowledge of European rheumatologists while
giving participants the opportunity to meet
and exchange ideas and experiences. The
comprehensive On-line Course on Rheumatic
Diseases together with specific courses on
RMDs provide trainees from all over the
world with the opportunity to acquire a
strong base of expertise in RMDs and the
latest insights into assessment and treatment.
In 2014, a total of 1642 registrations were
recorded.
Since its introduction in 2000, the Annual
European Congress of Rheumatology has
become the primary platform for exchange
of scientific and clinical information in
Europe as well as a renowned forum for
interaction between practising or training
physicians, scientists, people with arthritis/
rheumatism, health professionals and repre-
sentatives of the pharmaceutical industry
worldwide. The number of abstracts have
increased considerably during recent years,
but in particular an increase in the number
of scientific contributions has been observed,
with 4041 submitted abstracts for the EULAR
Congress in 2014.
RMDs impose an economic burden of over
€200 billion per year in Europe alone, where
at least 120 million pople are affected. A
further mission for EULAR is to support
research projects looking at different aspects
of rheumatology and funding collaborative
research between European rheumatology
groups. To this end, EULAR and the linked
foundation for rheumatological research
(FOREUM) provides substantial grants every
year.
Therefore, the EULAR Standing Committees
regularly publish recommendations for the
diagnosis and treatment of various rheumatic
disorders. These recommendations and set of
criteria are developed by experts, including
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patients, and are published in the EULAR journal, the
Annals of the Rheumatic Diseases (ARD, ard.bmj.com). First
published in 1939, ARD has been the official scientific pub-
lication of EULAR since 2000, and is now the number one
ranked (original research) journal in the field for the sixth
consecutive year, with an impact factor of 9.270.
So why does EULAR need another journal, another
communication platform? As RMDs become more recog-
nised as an important global burden disease, as evi-
denced by the recent EU investment, more and more
research is funded and carried out, with the aim of
improving outcomes for patients with these chronic dis-
eases. ARD has been receiving an increasing number of
submitted papers over the last years from about 1600 in
2008 to about 2000 submissions in 2014. The acceptance
rate has decreased and is now between 15% and 20%,
which means that many important papers, as well as pre-
liminary, negative or smaller scale studies, remain unvail-
able to the EULAR community in this journal. Moreover,
many funders mandate that research should be publicly
available through Open Access publication; we feel that
the rheumatology research landscape should provide as
full a picture as possible to meet the needs of researchers
and fully inform the ongoing improvements in healtcare
outcomes. RMD Open will therefore combine the benefits
of Open Access while always maintaining a high standard
of scientific rigour in the form of peer reviews expected
by EULAR and BMJ. These elements, together with an
experienced and respected editorial team of experts led
by Professor Bernard Combe, Editor-in-Chief, and the
trusted brands of EULAR and BMJ, will insure that
the research community is provided with a high quality,
valuable and trustworthy new resource.
RMD Open aims to publish any well-conducted study or
design protocol that adds to the overall body of knowl-
edge available in the public domain, in the areas of
basic/translational as well as clinical science. These will
be freely available, unrestricted, to research globally and
published online within 20 days of acceptance.
In the intial stages, readers will determine the influ-
ence of RMD Open papers on an individual basis rather
than by impact factor, which will certainly grow over
time. Article-level metrics, which will include downloads,
views and citations, will be provided, and readers will
have the opportunity to engage through rapid responses
available in each article. The impact of articles through
sharing on social media sites, public media activity and
twitter will all add to the overall influence of the pub-
lished research.
RMD Open will provide authors with visibility and a
global audience—and a trustworthy home for high-
quality research. We are confident that RMD Open will
soon be an important journal and communication plat-
form for the entire rheumatological community.
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